Based on data from @ MD patients of a @-week randomised , placebo-controlled trial comparing mirtazapine ( MIR ) and paroxetine ( PAR ) , the discriminative and predictive validity of EI for ( stable ) remission at treatment end was evaluated for seven subscales and the HAMD@ in the total and in treatment subgroups ( MIR vs. PAR ) .